4/27/2015 1:00:51 PM - <p>Pulling back today after spiking to new highs with recent volume-driven gains. Rallied on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base. Prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em></p><br><hr>4/24/2015 12:57:16 PM - <p>Hitting another new high today. Spiked to new highs with recent volume-driven gains on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base. Prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em></p><br><hr>4/22/2015 12:47:41 PM - <p>Gapped up for another new high on the prior session. Spiked to new highs with recent volume-driven gains on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em></p><br><hr>4/21/2015 12:40:23 PM - Gapped up today for another new high. Spiked to a new highs with recent volume-driven gains on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>4/10/2015 12:37:45 PM - Spiked to a new highs with volume-driven gains on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>4/9/2015 12:56:57 PM - Spiking to a new highs with volume-driven gains on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>4/8/2015 12:54:34 PM - Spiking to a new high on news it offered <strong>$29</strong> Billion to buy Perrigo Co Plc (PRGO). Completed a Secondary Offering on 3/31/15. Found support near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>3/30/2015 12:29:55 PM - Gapped down today, slumping near prior highs and its 50 DMA line. With big volume-driven gains it rallied from an orderly base, but prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>3/13/2015 12:33:47 PM - Pulling back today from a new 52-week high following <strong>2</strong> consecutive big volume-driven gains as it rallied from an orderly base. The 3/12/15 mid-day report noted - <em>&quot;Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (</em><a href="/StockProfiles/StockProfile.asp?symbol=ABT"><em>ABT</em></a><em>) generic drug business for <strong>$5.3</strong> billion.&quot; </em><br><hr>3/12/2015 12:33:07 PM - Hitting new 52-week highs with today&#39;s <strong>2</strong>nd consecutive big volume-driven gain, rallying from an orderly base. Reported earnings <strong>+35%</strong> on <strong>+15%</strong> sales for the Dec &#39;14 quarter, its<strong> 2</strong>nd consecutive quarterly comparison above the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria).Prior quarterly comparisons showed sub par sales revenues and earnings, however its annual earnings (<strong>A</strong> criteria) history has been good. Made gradual progress since noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (<a href="/StockProfiles/StockProfile.asp?symbol=ABT">ABT</a>) generic drug business for <strong>$5.3</strong> billion.<br><hr>10/31/2014 12:38:24 PM - Gapped up today clearing prior highs and challenging its 52-week high. Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Sep &#39;14 quarter but fundamental concerns remain. Prior comparisons were below the <strong>+25%</strong> minimum earnings increase (<strong>C</strong> criteria). Last noted in the 7/15/14 mid-day report after announcing plans to purchase Abbott Labs&#39; (<a href="/StockProfiles/StockProfile.asp?symbol=ABT">ABT</a>) generic drug business for <strong>$5.3</strong> billion.<br><hr>7/15/2014 12:53:31 PM - Consolidating above its 50 DMA line, trading above average volume for a <strong>2</strong>nd consecutive session after saying it would purchase Abbott Labs&#39; (<a href="/StockProfiles/StockProfile.asp?symbol=ABT">ABT</a> generic drug business for <strong>$5.3</strong> billion. Reported earnings <strong>+6%</strong> on <strong>+5%</strong> sales revenues for the Mar &#39;14 quarter. Fundamental concerns remain as quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>6</strong> quarters.&quot;<br><hr>4/25/2014 12:36:14 PM - Rebounding above its 50 DMA line with today&#39;s <strong>5</strong>th consecutive gain on ever-increasing volume. Last noted with caution in the 4/04/14 mid-day report - <em>&quot;Reported earnings <strong>+20%</strong> on <strong>+5%</strong> sales revenues for the Dec &#39;13 quarter. Fundamental concerns remain as quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>5</strong> quarters.&quot; </em><br><hr>4/4/2014 12:19:25 PM - Gapped up today, now trading <strong>-9.4%</strong> off its 52-week high. Found support near its 50 DMA line during its consolidation since last noted with caution in the 3/14/14 mid-day report - <em>&quot;Reported earnings <strong>+20%</strong> on <strong>+5%</strong> sales revenues for the Dec &#39;13 quarter. Fundamental concerns remain as quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>5</strong> quarters.&quot; </em><br><hr>3/14/2014 12:26:17 PM - Consolidating <strong>-8.1%</strong> off its 52-week high. Reported earnings <strong>+20%</strong> on <strong>+5%</strong> sales revenues for the Dec &#39;13 quarter. Fundamental concerns remain as quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>5</strong> quarters.<br><hr>2/27/2014 12:48:43 PM - Gapped up today hitting yet another new 52-week high tallying a considerable volume-driven gain. Fundamental concerns remain as prior mid-day reports cautioned members - <em>&quot;Reported earnings <strong>-1%</strong> on <strong>-2%</strong> sales revenues for the Sep &#39;13 quarter. Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>2/20/2014 12:39:41 PM - Hitting another new 52-week high today and making a <strong>3</strong>rd consecutive mid-day report appearance tallying considerable volume-driven gains. Fundamental concerns remain as when the 10/31/13 mid-day report cautioned members - <em>&quot;Reported earnings <strong>-1%</strong> on <strong>-2%</strong> sales revenues for the Sep &#39;13 quarter. Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>2/19/2014 1:00:04 PM - Hitting another new 52-week high today and making a <strong>2</strong>nd consecutive mid-day report appearance tallying a considerable volume-driven gain. Fundamental concerns remain as when the 10/31/13 mid-day report cautioned members - <em>&quot;Reported earnings <strong>-1%</strong> on <strong>-2%</strong> sales revenues for the Sep &#39;13 quarter. Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>2/18/2014 12:38:37 PM - Gapped up today and hit a new 52-week high. Last noted in the 10/31/13 mid-day report with caution - <em>&quot;Reported earnings <strong>-1%</strong> on <strong>-2%</strong> sales revenues for the Sep &#39;13 quarter. Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>10/31/2013 12:56:38 PM - Sputtering near its 50 DMA line today while enduring more distributional pressure. Reported earnings <strong>-1%</strong> on <strong>-2%</strong> sales revenues for the Sep &#39;13 quarter. Slumping with volume-driven losses since last noted in the 10/18/13 mid-day report with caution - <em>&quot;Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>10/18/2013 12:51:48 PM - Hovering near its 52-week high. Held its ground stubbornly and made gradual progress since last noted in the 9/10/13 mid-day report with caution - <em>&quot;Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>9/10/2013 12:32:01 PM - Gapped up today and hit a new 52-week high today, clearing sound flat base above its 50 DMA line with a considerable volume-driven gain. Prior mid-day reports cautioned - <em>&quot;Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>8/7/2013 1:29:32 PM - Perched at its 52-week high today, extended from any sound base following a spurt of volume-driven gains. The 8/05/13 mid-day report cautioned - <em>&quot;Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.&quot; </em><br><hr>8/5/2013 12:52:31 PM - Perched at its 52-week high today, extended from any sound base following a spurt of volume-driven gains. Reported earnings <strong>+13%</strong> on <strong>+1%</strong> sales revenues for the Jun &#39;13 quarter. Quarterly results were below the <strong>+25%</strong> minimum earnings increase for the past <strong>3</strong> quarters.<br><hr>11/16/2012 12:21:03 PM - Hovering near its 52-week high today, holding its ground following a recent spurt of volume-driven gains. Prior mid-day reports noted - <em>&quot;Reported earnings <strong>+51%</strong> on <strong>+15%</strong> sales revenues for the Sep &#39;12 quarter. Quarterly results were below the<strong>+25%</strong> minimum earnings increase for the prior <strong>3</strong> quarters.&quot; </em><br><hr>11/12/2012 12:42:30 PM - Hitting another new 52-week high today. Held its ground following a recent spurt of volume-driven gain. The 10/26/12 mid-day report noted - <em>&quot;Reported earnings <strong>+51%</strong> on <strong>+15%</strong> sales revenues for the Sep &#39;12 quarter. Quarterly results were below the<strong>+25%</strong> minimum earnings increase for the prior <strong>3</strong> quarters.&quot; </em><br><hr>10/26/2012 12:20:09 PM - Hit a new 52-week high today with its <strong>3</strong>rd consecutive volume-driven gain. Reported earnings <strong>+51%</strong> on <strong>+15%</strong> sales revenues for the Sep &#39;12 quarter. Quarterly results were below the<strong>+25%</strong> minimum earnings increase for the prior <strong>3</strong> quarters.<br><hr>4/1/2010 1:20:22 PM - Hit a new 52-week high today. Its annual earnings history (<strong>A</strong> criteria) and sales revenues are below the investment system&#39;s guidelines, yet it has shown better than <strong>+25%</strong> earnings increases for the past <strong>5</strong> quarters.<br><hr>10/29/2009 12:31:21 PM - Gapped up today, rallying up from support at its 50 DMA line. Fundamentally, its annual earnings history (<strong>A</strong> criteria) and sales revenues are unfavorable with respect to the investment system&#39;s guidelines.<br><hr>5/14/2009 12:22:50 PM - Gapped down today, technically under its 50 DMA line and violating its recent chart lows.   Fundamentally, its annual earnings history (the A criteria) is also unfavorable with respect to the investment system&#39;s guidelines.<br><hr>